UTv Videos

"Overall, our conclusion is we observed more benefit in apalutamide vs abiraterone," says Mehmet Asim Bilen, MD.

"I think these results particularly apply to practicing urologists that have the opportunity to train residents," says Kathryn Marchetti, MD.

“The patients with CDK12, the combination had a PSA50 of about 83% compared to the ABI/placebo of about only 62%,” says Neal D. Shore, MD.

"We identified that in our site, we were ordering almost 1600 cystoscopy packs. A lot of the materials that were in those packages were unnecessary for an outpatient procedure," says Malissa Williams.

“We wanted to do a modeling analysis using patient-level data to see if we can estimate whether or not there is a long-term cure or overall survival benefit for these patients,” says Daniel M. Geynisman, MD.

“My goal was very simple. Five years from now, there will be X number of more fathers, brothers, grandfathers who will be having dinners with their families because of what I'm doing, because I will find the cancer early and hopefully make an impact,” says Ashutosh Tewari, MD.

"Overall, our conclusion is, in this real-world analyses, more patients treated with apalutamide survive by 24 months following treatment initiation compared to enzalutamide," says Mehmet Asim Bilen, MD.

"In other words, we expected a higher infection rate after transrectal biopsy, however that 1.4% with our current sample size, we weren't powered to detect a significant difference," says Jim C. Hu, MD, MPH.

"I think it's important to try to mix up your visits with patients that you think might be a little shorter, like a vasectomy consult, vs a new patient visit for infertility that may take a little bit longer, so that you don't run over time," says Helen L. Bernie, DO, MPH.

“We see the pathways of PD-1 resistance being explored across oncology. Kidney cancer is not especially leading the way on that,” says Mayer Fishman, MD, PhD.

“We looked at MRD negative patients, MRD positive patients, and their ultimate clinical response to see if it could be predictive of recurrence-free survival,” says Vikram M. Narayan, MD.

"What we found was that the obedience to the upgrading criteria of PI-RADS as they are today resulted in a better overall outcome for all the patients that were included in the study," says Leonardo Kayat Bittencourt, MD, PhD.

“The American Cancer Society suspects that over 300,000 men will be newly diagnosed with prostate cancer this year, which is still a lot,” says Adam B. Weiner, MD.

"I think people don't understand how exhausting it is for people to manage these symptoms day in and day out," says Leslie Rickey, MD, MPH.

"In this study, we found no difference in patient-reported bowel toxicity in men receiving radiation plus relugolix vs radiation plus leuprolide," says Sagar A. Patel, MD.

"Real-world data has a real place in demonstrating some of these findings and allowing us to ask better questions," says Bogdana Schmidt, MD, MPH.

“I think that having the clinical context such as the PSA, the Gleason score, the other features that assess the aggressiveness of the disease can really help with some of these subtle findings that can be found on PET imaging,” says Daniel Spratt, MD.

"There's...this concept of the virtualist; truly, the virtual urologist who has a potentially full-time telehealth practice but geared toward really delivering care, and these positions exist," says Kara L. Watts, MD.

"The SPICI study is a randomized phase 3 [trial] asking the question of de-escalation," says Laurence Albiges, MD, PhD.

"We hope that this study will build a roadmap to personalized therapeutic advice for patients with advanced prostate cancer and potentially will improve their quality of life and outcomes," says Antonina Mitrofanova, PhD.

“When we compared the performance of the 4Kscore with and without the race coefficient, we found that this coefficient improved the calibration or accuracy of this model,” says Helen Y. Hougen, MD.

"This may be a way of treating earlier stage aggressive prostate cancer with chemotherapy and selecting patients based upon their biological profiles," says Daniel P. Petrylak, MD.

Kevin M. Wymer, MD, shares the take-home messages from the recent Urology paper, “Evaluation of Private Payer and Patient Out of Pocket Costs Associated with the Surgical Management of Benign Prostatic Hyperplasia.”

"I think probably the area getting the most attention nowadays is advances in robotic and minimally invasive surgery," says Miriam Harel, MD.

“The gemcitabine/docetaxel [combination] has been the answer that many people have needed,” says Joshua J. Meeks, MD, PhD.

"I probably see about 20% of my patients a week via telemedicine right now," says Helen L. Bernie, DO, MPH.

"The world has a way of sending you the same message until you get it, and burnout is the same way. It's going to keep coming at you until you acknowledge it," says Anne M. Suskind, MD, MS, FACS, FPMRS.